Search Results - "Wallin, Å. K."

CSF biomarkers predict a more malignant outcome in Alzheimer disease by WALLIN, A. K, BLENNOW, K, ZETTERBERG, H, LONDOS, E, MINTHON, L, HANSSON, O

“…To investigate if patterns of CSF biomarkers (T-tau, P-tau, and Abeta42) can predict cognitive progression, outcome of cholinesterase inhibitor (ChEI)…”
Get full text

Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease? by Wallin, Å. K., Hansson, O., Blennow, K., Londos, E., Minthon, L.

“…Objective The main objective of this study was to investigate possible predictors of response to cholinesterase inhibitor (ChEI) treatment, including…”
Get full text

CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival by Wallin, A K, Blennow, K, Andreasen, N, Minthon, L

“…Cerebrospinal fluid (CSF) samples from 21 patients with a clinical diagnosis of Alzheimer's disease (AD) participating in a 5-year treatment study with the…”
Get more information

Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease by Parnetti, L., Chiasserini, D., Andreasson, U., Ohlson, M., Hüls, C., Zetterberg, H., Minthon, L., Wallin, Å. K., Andreasen, N., Talesa, V. N., Blennow, K.

“…Parnetti L, Chiasserini D, Andreasson U, Ohlson M, Hüls C, Zetterberg H, Minthon L, Wallin ÅK, Andreasen N, Talesa VN, Blennow K. Changes in CSF acetyl‐ and…”
Get full text

Long-term rivastigmine treatment in a routine clinical setting by Minthon, L., Wallin, Å. K., Eriksson, S., Wattmo, C., Andreasen, N.

“…Objective –  The aim of the study was to observe the effects of long‐term rivastigmine treatment in patients with mild to moderate Alzheimer’s disease (AD) in…”
Get full text

Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy by Wallin, A K, Gustafson, L, Sjögren, M, Wattmo, C, Minthon, L

“…Fifty consecutive outpatients with Alzheimer's disease (AD) received treatment with the cholinesterase inhibitor tacrine in an open longitudinal study…”
Get more information

Risk Factors for Nursing Home Placement in Alzheimer's Disease: A Longitudinal Study of Cognition, ADL, Service Utilization, and Cholinesterase Inhibitor Treatment by Wattmo, Carina, Wallin, Asa K, Londos, Elisabet, Minthon, Lennart

“…Purpose of the Study: To identify risk factors for early nursing home placement (NHP) in Alzheimer's disease (AD), focusing on the impact of longitudinal…”
Get full text

A live video observatory reveals temporal processes at a shelf-depth whale-fall by GLOVER, Adrian G, HIGGS, Nicholas D, KÄLLSTRÖM, Björn, DAHLGREN, Thomas G, BAGLEY, Philip M, CARLSSON, Ralph, DAVIES, Andrew J, KEMP, Kirsty M, LAST, Kim S, NORLING, Karl, ROSENBERG, Rutger, WALLIN, Karl-Anders

“…There have been very few studies of temporal processes at chemosynthetic ecosystems, even at relatively more accessible shallow water sites. Here we report the…”
Get full text

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype by Vermunt, Lisa, Sikkes, Sietske A.M., van den Hout, Ardo, Handels, Ron, Bos, Isabelle, van der Flier, Wiesje M., Kern, Silke, Ousset, Pierre-Jean, Maruff, Paul, Skoog, Ingmar, Verhey, Frans R.J., Freund-Levi, Yvonne, Tsolaki, Magda, Wallin, Åsa K., Olde Rikkert, Marcel, Soininen, Hilkka, Spiru, Luisa, Zetterberg, Henrik, Blennow, Kaj, Scheltens, Philip, Muniz-Terrera, Graciela, Visser, Pieter Jelle, Vellas, B., Reynish, E., Ousset, P.J., Andrieu, S., Burns, A., Pasquier, F., Frisoni, G., Salmon, E., Michel, J.P., Zekry, D.S., Boada, M., Dartigues, J.F., Olde-Rikkert, M.G.M., Rigaud, A.S., Winblad, B., Malick, A., Sinclair, A., Frölich, L., Scheltens, P., Ribera, C., Touchon, J., Robert, P., Salva, A., Waldemar, G., Bullock, R., Tsolaki, M., Rodriguez, G., Spiru, L., Jones, R.W., Stiens, G., Stoppe, G., Eriksdotter Jönhagen, M., Cherubini, A., Lage, P.M., Gomez-Isla, T., Camus, V., Agüera-Morales, E., Lopez, F., Savy, S., Cantet, C., Coley, N.

“…We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting,…”
Get full text

Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer’s disease: CSF AChE activity after long-term treatment with AchEIs by Parnetti, L., Chiasserini, D., Andreasson, U., Ohlson, M., Hüls, C., Zetterberg, H., Minthon, L., Wallin, Å. K., Andreasen, N., Talesa, V. N., Blennow, K.

Get full text

Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting by Wallin, Asa K, Wattmo, Carina, Minthon, Lennart

“…In the absence of long-term, placebo-controlled studies of cholinesterase inhibitors in Alzheimer's disease (AD), analysis of the results of open-label trials…”
Get full text

Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes by van Waalwijk van Doorn, Linda J C, Gispert, Juan D, Kuiperij, H Bea, Claassen, Jurgen A H R, Arighi, Andrea, Baldeiras, Inês, Blennow, Kaj, Bozzali, Marco, Castelo-Branco, Miguel, Cavedo, Enrica, Emek-Savaş, Derya D, Eren, Erden, Eusebi, Paolo, Farotti, Lucia, Fenoglio, Chiara, Ormaechea, Juan Fortea, Freund-Levi, Yvonne, Frisoni, Giovanni B, Galimberti, Daniela, Genc, Sermin, Greco, Viviana, Hampel, Harald, Herukka, Sanna-Kaisa, Liu, Yawu, Lladó, Albert, Lleó, Alberto, Nobili, Flavio M, Oguz, Kader K, Parnetti, Lucilla, Pereira, João, Picco, Agnese, Pikkarainen, Maria, de Oliveira, Catarina Resende, Saka, Esen, Salvadori, Nicola, Sanchez-Valle, Raquel, Santana, Isabel, Scarpini, Elio, Scheltens, Philip, Soininen, Hilkka, Tarducci, Roberto, Teunissen, Charlotte, Tsolaki, Magda, Urbani, Andrea, Vilaplana, Eduard, Visser, Pieter Jelle, Wallin, Asa K, Yener, Görsev, Molinuevo, José L, Meulenbroek, Olga, Verbeek, Marcel M

“…Cerebrospinal fluid (CSF) biomarkers may support the diagnosis of Alzheimer's disease (AD). We studied if the diagnostic power of AD CSF biomarker…”
Get more information

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study by Visser, Pieter Jelle, MD, Verhey, Frans, MD, Knol, Dirk L, PhD, Scheltens, Philip, MD, Wahlund, Lars-Olof, PhD, Freund-Levi, Yvonne, MD, Tsolaki, Magda, MD, Minthon, Lennart, MD, Wallin, Åsa K, MD, Hampel, Harald, MD, Bürger, Katharina, MD, Pirttila, Tuula, MD, Soininen, Hilkka, MD, Rikkert, Marcel Olde, MD, Verbeek, Marcel M, PhD, Spiru, Luiza, MD, Blennow, Kaj, MD

“…Summary Background Alzheimer's disease (AD) pathology is common in patients with amnestic mild cognitive impairment (aMCI) without dementia, but the prevalence…”
Get full text

Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting by Wallin, Asa K, Andreasen, Niels, Eriksson, Sture, Båtsman, Stellan, Nasman, Birgitta, Ekdahl, Anne, Kilander, Lena, Grut, Mikaela, Rydén, Marie, Wallin, Anders, Jonsson, Mikael, Olofsson, Hasse, Londos, Elisabeth, Wattmo, Carina, Eriksdotter Jonhagen, Maria, Minthon, Lennart

“…Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term…”
Get more information

The challenge of recruiting multimorbid older patients identified in a hospital database to a randomised controlled trial by Biegus, Karol R., Frobell, Richard B., Wallin, Åsa K., Ekdahl, Anne W.

“…Background Research involving multimorbid older patients is gaining momentum. However, little is known about how to plan a randomised controlled trial (RCT)…”
Get full text

Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers by Handels, Ron L.H, Vos, Stephanie J.B, Kramberger, Milica G, Jelic, Vesna, Blennow, Kaj, van Buchem, Mark, van der Flier, Wiesje, Freund-Levi, Yvonne, Hampel, Harald, Olde Rikkert, Marcel, Oleksik, Ania, Pirtosek, Zvezdan, Scheltens, Philip, Soininen, Hilkka, Teunissen, Charlotte, Tsolaki, Magda, Wallin, Asa K, Winblad, Bengt, Verhey, Frans R.J, Visser, Pieter Jelle

“…Abstract Introduction We aimed to determine the added value of cerebrospinal fluid (CSF) to clinical and imaging tests to predict progression from mild…”
Get full text

Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting by Wattmo, Carina, Hansson, Oskar, Wallin, Asa K, Londos, Elisabet, Minthon, Lennart

“…To build and analyze regression models predicting (1) the long-term cognitive outcome in donepezil-treated patients with Alzheimer's disease, and (2) the…”
Get more information

Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline (vol 9, 101, 2017) by Bos, I, Verhey, FR, Ramakers, IHGB, Jacobs, HIL, Soininen, H, Freund-Levi, Y, Hampel, H, Tsolaki, M, Wallin, AK, van, Buchem MA

Get full text

The PSEN1 I143T mutation in a Swedish family with Alzheimer's disease: clinical report and quantification of Aβ in different brain regions by KELLER, Lina, WELANDER, Hedvig, CHIANG, Huei-Hsin, TJERNBERG, Lars O, NENNESMO, Inger, WALLIN, Asa K, GRAFF, Caroline

“…Early-onset dominantly inherited forms of Alzheimer's disease (AD) are rare, but studies of such cases have revealed important information about the disease…”
Get full text

Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application by Wattmo, Carina, Jedenius, Erik, Blennow, Kaj, Wallin, Asa K

“…Patients with Alzheimer's disease (AD) are currently treated with cholinesterase inhibitors, such as galantamine, without actual knowledge of its concentration…”
Get full text